Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Gizzi

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
The Journal of Biological Chemistry|March 2, 2013
An antedrug of the CXCL12 neutraligand blocks experimental allergic asthma without systemic effect in miceFrançois Daubeuf, Muriel Hachet-Haas, Patrick Gizzi, et al.
Molecular Informatics|December 27, 2023
Kinetic solubility: Experimental and machine-learning modeling perspectivesShamkhal Baybekov, Pierre Llompart, Gilles Marcou, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Prodrugs of a CXC Chemokine-12 (CXCL12) Neutraligand Prevent Inflammatory Reactions in an Asthma Model in VivoVincent Gasparik, François Daubeuf, Muriel Hachet-Haas, et al.
European Journal of Pharmacology|June 28, 2021
New contributions to the drug profile of TNFα inhibitor SPD304: Affinity, selectivity and ADMET considerationsAïda Mascret, Hadley Mouhsine, Ghada Attia, et al.
RSC Medicinal Chemistry|January 22, 2021
Discovery, SAR study and ADME properties of methyl 4-amino-3-cyano-1-(2-benzyloxyphenyl)-1<i>H</i>-pyrazole-5-carboxylate as an HIV-1 replication inhibitorJeanne Fichez, Cathia Soulie, Laurent Le Corre, et al.
Journal of Medicinal Chemistry|May 19, 2021
Identification of an <i>N</i>-acylated-<sup>D</sup>Arg-Leu-NH<sub>2</sub> Dipeptide as a Highly Selective Neuropeptide FF1 Receptor Antagonist That Potently Prevents Opioid-Induced HyperalgesiaRaphaëlle Quillet, Séverine Schneider, Valérie Utard, et al.
Scientific Reports|June 15, 2017
Identification of an in vivo orally active dual-binding protein-protein interaction inhibitor targeting TNFα through combined in silico/in vitro/in vivo screeningHadley Mouhsine, Hélène Guillemain, Gabriel Moreau, et al.
Nature|June 11, 2025
Targeting GRPR for sex hormone-dependent cancer after loss of E-cadherinJérémy H Raymond, Zackie Aktary, Marie Pouteaux, et al.
Journal of Medicinal Chemistry|August 15, 2018
Discovery of a Locally and Orally Active CXCL12 Neutraligand (LIT-927) with Anti-inflammatory Effect in a Murine Model of Allergic Airway HypereosinophiliaPierre Regenass, Dayana Abboud, François Daubeuf, et al.
The Journal of Biological Chemistry|June 17, 2008
Small neutralizing molecules to inhibit actions of the chemokine CXCL12Muriel Hachet-Haas, Karl Balabanian, François Rohmer, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
The Journal of Biological Chemistry|March 2, 2013
An antedrug of the CXCL12 neutraligand blocks experimental allergic asthma without systemic effect in miceFrançois Daubeuf, Muriel Hachet-Haas, Patrick Gizzi, et al.
Molecular Informatics|December 27, 2023
Kinetic solubility: Experimental and machine-learning modeling perspectivesShamkhal Baybekov, Pierre Llompart, Gilles Marcou, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Prodrugs of a CXC Chemokine-12 (CXCL12) Neutraligand Prevent Inflammatory Reactions in an Asthma Model in VivoVincent Gasparik, François Daubeuf, Muriel Hachet-Haas, et al.
European Journal of Pharmacology|June 28, 2021
New contributions to the drug profile of TNFα inhibitor SPD304: Affinity, selectivity and ADMET considerationsAïda Mascret, Hadley Mouhsine, Ghada Attia, et al.
RSC Medicinal Chemistry|January 22, 2021
Discovery, SAR study and ADME properties of methyl 4-amino-3-cyano-1-(2-benzyloxyphenyl)-1<i>H</i>-pyrazole-5-carboxylate as an HIV-1 replication inhibitorJeanne Fichez, Cathia Soulie, Laurent Le Corre, et al.
Journal of Medicinal Chemistry|May 19, 2021
Identification of an <i>N</i>-acylated-<sup>D</sup>Arg-Leu-NH<sub>2</sub> Dipeptide as a Highly Selective Neuropeptide FF1 Receptor Antagonist That Potently Prevents Opioid-Induced HyperalgesiaRaphaëlle Quillet, Séverine Schneider, Valérie Utard, et al.
Scientific Reports|June 15, 2017
Identification of an in vivo orally active dual-binding protein-protein interaction inhibitor targeting TNFα through combined in silico/in vitro/in vivo screeningHadley Mouhsine, Hélène Guillemain, Gabriel Moreau, et al.
Nature|June 11, 2025
Targeting GRPR for sex hormone-dependent cancer after loss of E-cadherinJérémy H Raymond, Zackie Aktary, Marie Pouteaux, et al.
Journal of Medicinal Chemistry|August 15, 2018
Discovery of a Locally and Orally Active CXCL12 Neutraligand (LIT-927) with Anti-inflammatory Effect in a Murine Model of Allergic Airway HypereosinophiliaPierre Regenass, Dayana Abboud, François Daubeuf, et al.
The Journal of Biological Chemistry|June 17, 2008
Small neutralizing molecules to inhibit actions of the chemokine CXCL12Muriel Hachet-Haas, Karl Balabanian, François Rohmer, et al.
Pageof 3